Bibliografia
1. Colivicchi F, Abrignani MG, Santini M. Aderenza terapeutica: il fattore di rischio occulto (G Ital Cardiol 2010; 11(5 Suppl 3):124S-127S.
2. Cramer JA, Roy A, Burrell A et al. Medication Compliance and Persistence: Terminology and Definitions. ISPOR 2008; 11(1):44-47.
3. Santi I, Zanoni CI, Cetta F. Fattori determinanti l’aderenza alla terapia farmacologica per l’osteoporosi e possibili strategie per migliorarla. G Gerontol 2010; 58:110-11
4. World Health Organization. Adherence to longterm therapies: evidence for action 2003.
5. Miselli V. G It Diabetol Metab 2011; 31:121-124.
6. Faught E. Adherence to antiepilepsy drug therapy. Epilepsy & Behavior 2012; 25:297-302.
7. Briesacher BA, Andrade SE, Fouayzi H et al. Comparison of Drug Adherence Rates Among Patients with Seven Different Medical Conditions. Pharmacotherapy 2008; 28(4):437-443.
8. Gabr WM, Shams ME. Adherence to medication among outpatient adolescents with epilepsy. Saudi Pharmaceutical Journal (2015); 23:33.40.
9. Brown I, Sheeran P, Reuber M. Enhancing antiepileptic drug adherence: A randomized controlled trial. Epilepsy & Behavior 2009;16:634- 639.
10. Sweileh WM, Ihbesheh MS, Jarar IS et al. Selfreported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy & Behavior 2011; 21:301-305.
11. Ettinger AB, Good MB, Ranjani Manjunath R et al. The relationship of depression to antiepileptic drug adherence and quality of life in epilepsy. Epilepsy & Behavior 36 (2014):138-143.
12. Eatock J, Baker GA. Managing patient adherence and quality of life in epilepsy. Neuropsychiatric Disease and Treatment 2007; 3(1):117-131.
13. Trinka E. Ideal characteristics of an antiepileptic drug: how do these impact treatment decisions for individual patients? Acta Neurol Scand 2012; 126(Suppl. 194):10-18.
14. NICE clinical guideline 76. Medicines adherence. Involving patients in decisions about prescribed medicines and supporting adherence. NICE 2009.
15. Baulac M, Brodie MJ, Patten A et al. Efficacy and tolerability of zonisamide versus controlledrelease carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, doubleblind, non-inferiority trial. Lancet Neurol 2012; 11(7):579-588.
16. Baulac M, Patten A, Giorgi L. Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: Results of a phase III, randomized, double-blind study. Epilepsia 2014; 55(10):1534- 1543.
17. Hoy SM. Zonisamide: a review of its use in the management of adults with partial seizures. Drugs 2013; 73(12):1321-1338.
|